Xingwei D. Sui
Expertise in
60
conditions

Dr. Xingwei D. Sui

Hematology | Oncology
954 Anderson Drive, Suite 102, 
Aberdeen, WA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
60
conditions
954 Anderson Drive, Suite 102, 
Aberdeen, WA 

Overview

Dr. Sui earned a medical degree from Qingdao University, China, and a Ph.D. from the University of Tokyo, Japan. He conducted postdoctoral research in hematology at Vanderbilt University, an internal medicine residency at the University of Tennessee, and a medical oncology fellowship at the Fred Hutchinson Cancer Research Center and the University of Washington. He is board certified in internal medicine and medical oncology. He was an associate professor at Shangdong. Dr. Sui believes in treating his patients as if they were his own family members.

Dr. Sui is highly rated in 60 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Lung Cancer, Pleuropulmonary Blastoma, and Large-Cell Immunoblastic Lymphoma.

Dr. Sui is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 3 clinical trials. Dr. Sui is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in WA

Board Certifications

American Board Of Internal Medicine

Fellowships

University of Washington Department Hematology Oncology Fellowship , 2005

Hospital Affiliations

Grays Harbor Community Hospital
Summit Pacific Medical Center
Providence Centralia Hospital
Providence St Peter Hospital

Languages Spoken

English
Filipino
French
Hindi
Japanese
Korean
Mandarin
Portuguese
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Lifewise

Accepted plan types not found. Please verify directly with the provider.

Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Prominence Health
  • EPO
  • PPO
Regence
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Providence Regional Cancer System - Aberdeen
954 Anderson Drive, Suite 102, Aberdeen, WA 98520

Additional Areas of Focus

Dr. Sui has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Thalassemia
Anemia
Langerhans Cell Histiocytosis
Hereditary Spherocytosis
Hemochromatosis
Histiocytosis
Breast Cancer
HELLP Syndrome
Splenomegaly
Thrombotic Thrombocytopenic Purpura
Purpura
Thrombocytopenia
Iron Deficiency Anemia
Leukocytosis
View 4 Less Areas of Focus-

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 1/2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors
A Phase 1/2, Open-Label, Multi-Arm Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors
Enrollment Status: Completed
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drugs: AGEN-2034 PD-1 Antibody, AGEN-1884 CTLA4 Antibody
Study Phase: Phase 1/Phase 2
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: X-396 (Ensartinib), Crizotinib
Study Phase: Phase 3
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Enrollment Status: Completed
Publish Date: May 27, 2022
Intervention Type: Biological
Study Phase: Phase 2
View 2 Less Clinical Trials

3 Total Publications

Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study.
Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study.
Journal: Journal for immunotherapy of cancer
Published: October 05, 2024
Similar Doctors
Expertise in
30
conditions
Dr. Mijung Lee
Hematology | Oncology
Expertise in
30
conditions
Dr. Mijung Lee
Hematology | Oncology
Referral may be required
Before you request

Providence Regional Cancer System - Aberdeen

954 Anderson Drive, Suite 102, 
Aberdeen, WA 
 (0.1 miles away)
360-533-6906
Languages Spoken:
English, Arabic, Hebrew, Hindi, Italian, Japanese, Korean, Mandarin, Somali, Spanish, Thai, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

I aspire to excellence in patient centered care via evidence-based medicine and value-based care of individual patients. I hope to be a creative contributor to the field of medicine I was called to and serve the community with joy of practicing medicine. I love music, reading, and biking. Dr. Lee is highly rated in 30 conditions, according to our data. Her clinical expertise encompasses Angiosarcoma, Paget Disease of the Breast, Inflammatory Breast Cancer, Astrocytoma, and Bone Marrow Aspiration. Dr. Lee is board certified in American Board Of Internal Medicine. Dr. Lee is currently accepting new patients.

Expertise in
34
conditions
Dr. Ahmad A. Fora
Hematology | Oncology
Expertise in
34
conditions
Dr. Ahmad A. Fora
Hematology | Oncology
Referral may be required

Vista Oncology Inc PS

141 Lilly Rd NE, 
Olympia, WA 
 (47.3 miles away)
360-413-8880
Languages Spoken:
English, Arabic, Bosnian, Filipino, Korean, Punjabi
See accepted insurances
Accepting New Patients
Offers Telehealth

Ahmad Fora is a Hematologist and an Oncologist practicing medicine in Olympia, Washington. Dr. Fora is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Essential Thrombocythemia, Thrombocytopenia, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Schnitzler Syndrome. Dr. Fora is currently accepting new patients.

Expertise in
26
conditions
Dr. James J. Lechner
Hematology | Oncology
Expertise in
26
conditions
Dr. James J. Lechner
Hematology | Oncology
Referral may be required
Before you request

Providence Centralia Hospital

914 South Scheuber Road, 
Centralia, WA 
 (47.8 miles away)
360-736-2803
Experience:
44+ years
Languages Spoken:
English, Hindi, Hungarian, Korean, Polish, Portuguese, Russian, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Lechner is a graduate of the University of California at Los Angeles School of Medicine. He completed his oncology and hematology training at Oregon Health & Science University in Portland. Dr. Lechner is board certified in medical oncology and internal medicine. Dr. Lechner is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Paget Disease of the Breast, and Large-Cell Immunoblastic Lymphoma. Dr. Lechner is board certified in American Board Of Internal Medicine. Dr. Lechner is currently accepting new patients.

Frequently Asked Questions about Dr. Xingwei D. Sui

How do I make an appointment with Dr. Xingwei D. Sui?

You can book an appointment with Dr. Xingwei D. Sui by calling their office at 360-533-6906. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Xingwei D. Sui a top-rated expert for Chronic Lymphocytic Leukemia (CLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Xingwei D. Sui is classified as an Distinguished expert for Chronic Lymphocytic Leukemia (CLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Xingwei D. Sui specialize in?

While Dr. Xingwei D. Sui is a Hematology, they have specific expertise in Chronic Lymphocytic Leukemia (CLL), Lung Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Xingwei D. Sui participate in research or clinical trials?

Yes. Dr. Xingwei D. Sui has published 3 articles and abstracts on conditions like Chronic Lymphocytic Leukemia (CLL). You can view a list of Dr. Xingwei D. Sui's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Xingwei D. Sui accept my insurance?

Dr. Xingwei D. Sui accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 360-533-6906 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sui's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 50 Advanced Conditions
    View All 101 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile